How much cash does Aquestive Therapeutics, Inc. generate?

Aquestive Therapeutics, Inc. (AQST) generated -$43.8M in operating cash flow over the trailing twelve months.

What is Aquestive Therapeutics, Inc.'s free cash flow?

After $479.0K of capital expenditures, Aquestive Therapeutics, Inc.'s free cash flow was -$44.3M over the trailing twelve months, up 9.6% year over year.

Where does Aquestive Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Aquestive Therapeutics, Inc. AQST Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	-$83.78M-89.8%	-$44.14M-461%	-$7.87M+85.5%	-$54.41M+22.9%
Depreciation and amortization	$548K-23.7%	$718K-46.6%	$1.35M-43.7%	$2.39M-19.5%
Stock-based compensation	$7.62M+7.4%	$7.1M+164%	$2.69M-38.6%	$4.38M-35.8%
Amortization of debt issuance costs	$11M+2.6%	$10.71M+443%	$1.97M+817%	$215K-94.2%
Change in inventories	——	-$725K—	——	——
Change in accounts payable	——	$2.78M—	——	——
Change in accrued liabilities	——	——	——	——
Change in other assets	——	$223K—	——	——
Other working capital changes	-$1K—	——	——	$52K—
Change in deferred revenue	——	-$12.84M—	——	$25.44M+577%
Change in receivables	$10.44M+1,054%	-$1.09M—	——	-$7.35M—
Net cash from operating activities	-$52.43M-46.6%	-$35.76M-460%	-$6.38M—	——
Capital expenditures	$562K+253%	$159K-84.0%	$995K-2.8%	$1.02M+12.2%
Net cash from investing activities	-$562K-253%	-$159K+84.0%	-$995K+60.6%	-$2.52M-176%
Repayments of debt	——	$23K—	——	——
Proceeds from issuance of common stock	$1.27M—	——	$1K—	——
Taxes paid for net share settlement	$810K-26.4%	$1.1M—	——	$3K-78.6%
Net cash from financing activities	$102.72M+22.9%	$83.61M+2,004%	$3.97M-66.1%	$11.73M-61.0%
Net increase (decrease) in cash	——	——	——	——
Interest paid	$6.1M-14.1%	$7.1M+54.2%	$4.6M-28.5%	$6.44M0.0%
Non-cash interest expense	$11M+2.6%	$10.71M+443%	$1.97M+817%	$215K-94.2%
Increase (Decrease) in Accounts and Other Receivables	$10.44M+1,054%	-$1.09M—	——	-$7.35M—
Accrued expenses and other liabilities	——	——	——	——
Deferred revenue	——	-$12.84M—	——	$25.44M+577%
Increase (Decrease) in Prepaid Expense and Other Assets	——	$223K—	——	——
Satisfaction of management and incentive fees in stock	——	——	——	——
Other Noncash Income (Expense)	-$1K—	——	——	$52K-82.6%
Payments for Royalty Obligations	——	$5K—	$0—	——
Proceeds from common stock issued under public equity offering-ATM, net	——	$11.78M+32.2%	$8.91M+128%	$3.91M-86.9%
Repayments of Debt	——	$23K—	——	——
Costs associated with public offering-ATM in Accounts Payable	——	——	——	——
Proceeds from Income Tax Refunds	$65K—	$0—	——	——
Non-cash financing activities: accrued taxes on share-based compensation	$0-100%	$250K—	$0—	——
Free cash flow	-$52.99M-47.5%	-$35.92M-387%	-$7.38M—	——
Free cash flow	-$52.99M-47.5%	-$35.92M-387%	-$7.38M—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Aquestive Therapeutics, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Aquestive Therapeutics, Inc. generate?: Aquestive Therapeutics, Inc. (AQST) generated -$43.8M in operating cash flow over the trailing twelve months.
What is Aquestive Therapeutics, Inc.'s free cash flow?: After $479.0K of capital expenditures, Aquestive Therapeutics, Inc.'s free cash flow was -$44.3M over the trailing twelve months, up 9.6% year over year.
Where does Aquestive Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.